secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001437749-25-035521
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health secures BARDA Techwatch meeting for Entolimod ARS program
----------------------------------------------------------------------

- Meeting with BARDA's Radiological and Nuclear Medical Countermeasures Program staff to discuss Entolimod for acute radiation syndrome.
- Tivic will present clinical data, manufacturing readiness, and BLA preparations; meeting may lead to funding or purchasing.
- Entolimod has FDA Fast Track and Orphan Drug designations for ARS.
- CEO states this supports strategy for government partnership or acquisition pathway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000143774925035521/0001437749-25-035521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000143774925035521/tivc20251117_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-035521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer